Genomics and Molecular Diagnostics Pioneer Charles Cantor, Ph.D., Joins Trovagene's Scientific Advisory Board
SAN DIEGO, March 26, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and Technology of the Human Genome Project.
"Charles is a renowned contributor to the genetics and life sciences fields, and we are honored that he has joined Trovagene as an advisor," stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. "As our cancer monitoring platform moves through the clinical validation stage and into clinical practice, Charles' experience in developing and commercializing groundbreaking diagnostic products based on cell-free DNA will be invaluable."
"Trovagene is positioned to offer a transformative solution for monitoring cancer by tracking oncogene mutations in urine samples," stated Dr. Cantor. "I am excited to work with the company's scientific team to realize the promise of this technology, which can provide a non-invasive molecular diagnostic option for physicians to more precisely treat cancer patients and achieve better outcomes."
Dr. Cantor is professor emeritus of Biomedical Engineering and of Pharmacology, and was the director of the Center for Advanced Biotechnology at Boston University. He is currently adjunct professor of Bioengineering at the University of California, San Diego, adjunct professor of Molecular Biology at The Scripps Research Institute, and distinguished adjunct professor of Physiology and Biophysics at the University of California, Irvine. Previously, Dr. Cantor held positions in Chemistry, Genetics and Development at Columbia University, and in Molecular Biology at the University of California at Berkeley.
Dr. Cantor is a founder, and former Chief Scientific Officer of Sequenom, Inc., a life sciences company that provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets. He is also the founder of Retrotope, Inc., a company focused on the development of compounds to treat degenerative diseases, and acts as a consultant for several companies within the biotechnology industry. He earned his bachelor's degree in chemistry at Columbia College, and his doctorate at the University of California Berkeley.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.
SOURCE Trovagene, Inc.